Cerebrovascular Diseases
Original Paper
Neurotransplantation of Fetal Porcine Cells in Patients with Basal Ganglia Infarcts: A Preliminary Safety and Feasibility StudySavitz S.I.a · Dinsmore J.b · Wu J.c · Henderson G.V.d · Stieg P.e · Caplan L.R.aDepartments of aNeurology and cNeurosurgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., bGenvec Inc., Charlestown, Mass., dDepartment of Neurology, Brigham and Women’s Hospital, Boston, Mass., eDepartment of Neurosurgery, New York Presbyterian Hospital, Weil Medical College of Cornell University, New York, N.Y., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: January 26, 2005
Accepted: April 11, 2005
Published online: July 29, 2005
Issue release date: July 2005
Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Background: Cell transplantation is safe in animal models and enhances recovery from stroke in rats. Methods: We studied the safety and feasibility of fetal porcine transplantation in 5 patients with basal ganglia infarcts and stable neurological deficits. To prevent rejection, cells were pretreated with an anti-MHC1 antibody and no immunosuppressive drugs were given to the patients. Results: The first 3 patients had no adverse cell, procedure, or imaging-defined effects. The fourth patient had temporary worsening of motor deficits 3 weeks after transplantation, and the fifth patient developed seizures 1 week after transplantation. MRI in both patients demonstrated areas of enhancement remote from the transplant site, which resolved on subsequent imaging. Two patients showed improvement in speech, language, and/or motor impairments over several months and persisted at 4 years. The study was terminated by the FDA after the inclusion of 5 patients. Conclusion: This is the first report on the transplantation of nontumor cells in ischemic stroke patients.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Savitz SI, Rosenbaum DM, Dinsmore JH, Wechsler LR, Caplan LR: Cell transplantation for stroke. Ann Neurol 2002;52:266–275.
- Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, Jannetta P, DeCesare S, Elder EM, McGrogan M, Reitman MA, Bynum L: Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000;55:565–569.
- Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH: Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995;1:1189–1194.
- Deacon TW, Pakzaban P, Burns LH, Dinsmore J, Isacson O: Cytoarchitectonic development, axon-glia relationships, and long distance axon growth of porcine striatal xenografts in rats. Exp Neurol 1994;130:151–167.
-
Dinsmore JH MJ, Siegan J, Morrison JP, Lindberg C, Ratliff J, Jacoby D: CNS grafts for treatment of neurologic disorders. Methods of Tissue Engineering, San Diego, Academic Press, 2002.
- Pakzaban P, Deacon TW, Burns LH, Dinsmore J, Isacson O: A novel mode of immunoprotection of neural xenotransplants: Masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 1995;65:983–996.
- Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, Penn R, Starr P, VanHorne C, Kott HS, Dempsey PK, Fischman AJ, Raineri R, Manhart C, Dinsmore J, Isacson O: Porcine xenografts in Parkinson’s disease and Huntington’s disease patients: Preliminary results. Cell Transplant 2000;9:273–278.
- Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, Fischman AJ, Thomas C, Feldman RG, Kassissieh S, Rai neri R, Manhart C, Penney D, Fink JS, Isacson O: Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 2000;54:1042–1050.
- Dinsmore JH, Manhart C, Raineri R, Jacoby DB, Moore A: No evidence for infection of human cells with porcine endogenous retrovirus (PERV) after exposure to porcine fetal neuronal cells. Transplantation 2000;70:1382–1389.
- Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O: Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson’s disease. Nat Med 1997;3:350–353.
-
Kondziolka D, Steinberg GK, Wechsler L, et al: Neurotransplantation for patients with subcortical motor stroke: A phase 2 randomized trial. J Neurosurg, in press.
- Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, Chopp M: Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001;32:1005–1011.
- Li Y, Chen J, Wang L, Lu M, Chopp M: Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology 2001;56:1666–1672.
Article / Publication Details
Received: January 26, 2005
Accepted: April 11, 2005
Published online: July 29, 2005
Issue release date: July 2005
Number of Print Pages: 7
Number of Figures: 2
Number of Tables: 3
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
